Market Overview

UPDATE: Bank of America Lowers Nektar Therapeutics PO, Maintains Underperform

Related NKTR
5 Healthcare Stocks With The Highest EPS Growth Forecast For Next 5 Years
Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 2

In a report published Tuesday, Bank of America lowered its price objective on Nektar Therapeutics (NASDAQ: NKTR) from $7.50 to $7.00 and maintained its Underperform rating.

Bank of America noted, "following top line ph 3 results for naloxegol in OIC, we have lowered our peak share to 5% (from 10%) in 2020, more than offsetting increased probability of approval. This has lowered our PO for NKTR shares to $7 from $7.50. While there is increased concern that NKTR/AZN may have to assess CV risk in naloxegol (unlikely in our view), we are more concerned about efficacy in the phase 3 studies (KODIAC-04 and -05). In the -05 study, the response rate for the lower dose (12.5mg) was not significant (p=0.202) and the 25mg dose just made the cutoff (p=0.021). Based on the statistical significance levels provided, and a standard deviation estimate derived from THRX and CBST studies, we estimate the PBOadjusted response rate for the 25mg naloxegol dose to be in the 11-16% range, well below the 30% levels achieved by the THRX and CBST drugs."

Nektar Therapeutics closed at $7.04 on Monday.

Latest Ratings for NKTR

Sep 2014Bank of AmericaMaintainsUnderperform
Sep 2014Brean CapitalMaintainsBuy
Jun 2014Ladenburg ThalmannInitiates Coverage onBuy

View More Analyst Ratings for NKTR
View the Latest Analyst Ratings

Posted-In: Bank of AmericaAnalyst Color Price Target Analyst Ratings


Related Articles (NKTR)

Around the Web, We're Loving...

Get Benzinga's Newsletters